Literature DB >> 25748573

Xylosyltransferase II is the predominant isoenzyme which is responsible for the steady-state level of xylosyltransferase activity in human serum.

Joachim Kuhn1, Christian Götting2, Brendan J Beahm3, Carolyn R Bertozzi3, Isabel Faust4, Patricia Kuzaj4, Cornelius Knabbe4, Doris Hendig4.   

Abstract

In mammals, two active xylosyltransferase isoenzymes (EC 2.4.2.16) exist. Both xylosyltransferases I and II (XT-I and XT-II) catalyze the transfer of xylose from UDP-xylose to select serine residues in the proteoglycan core protein. Altered XT activity in human serum was found to correlate directly with various diseases such as osteoarthritis, systemic sclerosis, liver fibrosis, and pseudoxanthoma elasticum. To interpret the significance of the enzyme activity alteration observed in disease states it is important to know which isoenzyme is responsible for the XT activity in serum. Until now it was impossible for a specific measurement of XT-I or XT-II activity, respectively, because of the absence of a suitable enzyme substrate. This issue has now been solved and the following experimental study demonstrates for the first time, via the enzyme activity that XT-II is the predominant isoenzyme responsible for XT activity in human serum. The proof was performed using natural UDP-xylose as the xylose donor, as well as the artificial compound UDP-4-azido-4-deoxyxylose, which is a selective xylose donor for XT-I.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glycosaminoglycan; Human serum; Mass spectrometry; Proteoglycan; Xylosyltransferase

Mesh:

Substances:

Year:  2015        PMID: 25748573      PMCID: PMC6598695          DOI: 10.1016/j.bbrc.2015.02.129

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Elevated serum xylosyltransferase activity correlates with a high level of hyaluronate in patients with systemic sclerosis.

Authors:  C Götting; J Kuhn; S Sollberg; C Huerkamp; T Brinkmann; T Krieg; K Kleesiek
Journal:  Acta Derm Venereol       Date:  2000 Jan-Feb       Impact factor: 4.437

2.  Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II.

Authors:  C Götting; J Kuhn; R Zahn; T Brinkmann; K Kleesiek
Journal:  J Mol Biol       Date:  2000-12-08       Impact factor: 5.469

3.  THE ROLE OF GALACTOSE AND XYLOSE IN THE LINKAGE OF HEPARIN TO PROTEIN.

Authors:  U LINDAHL; L RODEN
Journal:  J Biol Chem       Date:  1965-07       Impact factor: 5.157

4.  Studies on biosynthesis of the linkage region of chondroitin sulfate-protein complex.

Authors:  H C Robinson; A Telser; A Dorfman
Journal:  Proc Natl Acad Sci U S A       Date:  1966-12       Impact factor: 11.205

5.  Mutational and functional analyses of xylosyltransferases and their implication in osteoarthritis.

Authors:  S Schön; G Huep; C Prante; S Müller; R Christ; F-W Hagena; J Kuhn; K Kleesiek; C Götting
Journal:  Osteoarthritis Cartilage       Date:  2005-12-22       Impact factor: 6.576

6.  Biosynthesis of the linkage region of glycosaminoglycans: cloning and activity of galactosyltransferase II, the sixth member of the beta 1,3-galactosyltransferase family (beta 3GalT6).

Authors:  X Bai; D Zhou; J R Brown; B E Crawford; T Hennet; J D Esko
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

7.  Serum xylosyltransferase: a new biochemical marker of the sclerotic process in systemic sclerosis.

Authors:  C Götting; S Sollberg; J Kuhn; C Weilke; C Huerkamp; T Brinkmann; T Krieg; K Kleesiek
Journal:  J Invest Dermatol       Date:  1999-06       Impact factor: 8.551

8.  Cloning and expression of a proteoglycan UDP-galactose:beta-xylose beta1,4-galactosyltransferase I. A seventh member of the human beta4-galactosyltransferase gene family.

Authors:  R Almeida; S B Levery; U Mandel; H Kresse; T Schwientek; E P Bennett; H Clausen
Journal:  J Biol Chem       Date:  1999-09-10       Impact factor: 5.157

9.  First isolation of human UDP-D-xylose: proteoglycan core protein beta-D-xylosyltransferase secreted from cultured JAR choriocarcinoma cells.

Authors:  J Kuhn; C Götting; M Schnölzer; T Kempf; T Brinkmann; K Kleesiek
Journal:  J Biol Chem       Date:  2000-11-21       Impact factor: 5.157

10.  High-level expression and purification of human xylosyltransferase I in High Five insect cells as biochemically active form.

Authors:  Joachim Kuhn; Sandra Müller; Martina Schnölzer; Tore Kempf; Sylvia Schön; Thomas Brinkmann; Manuela Schöttler; Christian Götting; Knut Kleesiek
Journal:  Biochem Biophys Res Commun       Date:  2003-12-19       Impact factor: 3.575

View more
  5 in total

Review 1.  Endoglycosidases for the Synthesis of Polysaccharides and Glycoconjugates.

Authors:  Chao Li; Lai-Xi Wang
Journal:  Adv Carbohydr Chem Biochem       Date:  2016-08-23       Impact factor: 12.200

2.  First Characterization of Human Dermal Fibroblasts Showing a Decreased Xylosyltransferase-I Expression Induced by the CRISPR/Cas9 System.

Authors:  Bastian Fischer; Vanessa Schmidt; Thanh-Diep Ly; Anika Kleine; Cornelius Knabbe; Isabel Faust-Hinse
Journal:  Int J Mol Sci       Date:  2022-05-02       Impact factor: 6.208

3.  Exploration of human xylosyltransferase for chemoenzymatic synthesis of proteoglycan linkage region.

Authors:  Jia Gao; Po-Han Lin; Setare Tahmasebi Nick; Kunli Liu; Kefei Yu; Erhard Hohenester; Xuefei Huang
Journal:  Org Biomol Chem       Date:  2021-04-26       Impact factor: 3.876

Review 4.  Recent advances on glycosyltransferases involved in the biosynthesis of the proteoglycan linkage region.

Authors:  Jia Gao; Xuefei Huang
Journal:  Adv Carbohydr Chem Biochem       Date:  2021-11-24       Impact factor: 3.714

5.  UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

Authors:  Joachim Kuhn; Tatjana Gripp; Tobias Flieder; Marcus Dittrich; Doris Hendig; Jessica Busse; Cornelius Knabbe; Ingvild Birschmann
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.